Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunogenicity, Reactogenicity and Safety Study to Evaluate Two Doses of the Lyophilised Formulation of the Human Rotavirus (HRV) Vaccine When Administered to Healthy Korean Infants Previously Uninfected With HRV

NCT00969228 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00969228
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00969228 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunogenicity, Reactogenicity and Safety Study to Evaluate Two Doses of the Lyophilised Formulation of the Human Rotavirus (HRV) Vaccine When Administered to Healthy Korean Infants Previously Uninfected With HRV
Lead sponsor
GlaxoSmithKline
Phase
Phase 4
Overall status
Completed
Start date
August 25, 2009
Completion date
July 23, 2010
Enrollment
684 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

infections, rotavirus, rotavirus vaccines